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Abstract
Glutamate and gamma-aminobutyric acid (GABA) are themajor neurotransmitters in the
mammalian brain. Inhibitory GABA and excitatory glutamate work together to control
many processes, including the brain’s overall level of excitation. The contributions of
GABA and glutamate in extra-neuronal signaling are by far less widely recognized. In
this chapter, we first discuss the role of both neurotransmitters during development,
emphasizing the importance of the shift from excitatory to inhibitory GABAergic neuro-
transmission. The second part summarizes the biosynthesis and role of GABA and
glutamate in neurotransmission in the mature brain, and major neurological disorders
associated with glutamate and GABA receptors and GABA release mechanisms. The
final part focuses on extra-neuronal glutamatergic and GABAergic signaling in pancre-
atic islets of Langerhans, and possible associations with type 1 diabetes mellitus.
Keywords: glutamate, GABA, CNS, pancreatic islets, neurological disorders
autoimmune diabetes
1. Introduction
Glutamate and gamma-aminobutyric acid (GABA) are the major neurotransmitters in the
brain. Inhibitory GABA and excitatory glutamate work together to control many processes,
including the brain’s overall level of excitation. A balanced interaction is required to maintain
the physiological homeostasis, while prolonged imbalance can lead to disease. Glutamatergic/
GABAergic imbalance can be found in autism spectrum disorders and anxiety disorders with
elevated glutamatergic neurotransmission, while high levels of GABA produce more relaxa-
tion and even sedation. Neurotransmitter levels can be affected by external factors, for exam-
ple, alcohol. Alcohol potentiates the sedentary effects of GABA, while inhibiting the excitatory
aspects of glutamate, resulting in an overall increase in GABA/glutamate ratio. This leads to
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sensations of relaxation and in later stages to loss of control with slurred speech, unsteady gait
and loss of social anxiety. The GABA/glutamate balance can also be affected by autoimmunity
and genetic disorders. The contributions of GABA and glutamate in extra-neuronal signaling
are by far less recognized. We will discuss extra-neuronal GABAergic and glutamatergic
signaling and its relevance in insulin secretion from the pancreatic islets of Langerhans.
2. Glutamate and GABA during development
Both glutamatergic and GABAergic neurons are highly diversified in the central nervous
system (CNS). More than half a century after the discovery of the effects of GABA, it is now
established that in mature neurons, neuronal excitability is characterized by a balance between
glutamatergic excitatory input and GABAergic inhibitory transmission. This balance is reached
during development. However, the functions of GABAergic signaling are not restricted to a
pure inhibitory mechanism at the synaptic level. This is a too simplistic view. For instance,
GABA influences patterns and oscillations that are very relevant from the behavioral point of
view [1]. GABA and glutamate expression are already widespread in the embryonic stage, and
glutamate receptors are expressed in neurons even before glutamatergic synaptogenesis [1].
While glutamate receptor activities tune the developing GABAergic synapse [2], GABA is now
considered the main excitatory transmitter during early development, acting not only at a
synaptic and network level, but also on cell cycle and migration [1]. This excitatory function
of GABA is caused by elevated neuronal intracellular chloride concentration at the early
stages of development. The efflux of chloride mediated by GABA in immature neurons is
excitatory, triggering sodium spikes and activating voltage-gated Ca2+ channels [1]. With time,
a progressive reduction of chloride efflux occurs. This explains the shift from a depolarizing to
a hyperpolarizing effect. Obata and colleagues were the first to suggest this developmentally
regulated shift at the level of the spinal cord [3]. Neuronal chloride homeostasis is regulated by
channels, exchangers and co-transporters. The developmental changes of sodium-potassium-
chloride cotransporter 1 (NKCC1) (ensuring chloride uptake; higher expression in immature
neurons) and potassium-chloride transporter 2 (KCC2) (principal chloride extruder; higher
expression in mature neurons) are the masterpieces for the changes in chloride efflux associated
with maturation. The developmental shift from local to large-scale network activity occurs in
parallel with a gradual shift from electrical to chemical synaptic transmission [4].
It is noteworthy that in immature neurons activation of GABAA receptors leads to an increase
in the intra-cellular concentration of Ca2+, as a consequence of the stimulation of voltage-gated
Ca2+ channels, which exerts trophic effects on neuritic growth, migration and synaptogenesis.
Blocking the GABAA receptor reduces the cytoplasmic concentrations of Ca
2+ [5]. In addition,
the activation of GABAB receptors depresses the GABAA receptor-mediated Ca
2+ increase and
therefore the GABAB pathway is likely supervising the entry of Ca
2+ [6]. In granule cells of the
cerebellum, the changes in the concentrations of Ca2+ outlast the exposure to GABA by several
minutes [7]. The GABAA-activated Ca
2+ influx regulates the expression of the chloride extruder
KCC2 [8]. One example of the relevance of this physiological shift in the chloride gradient
occurs during delivery when the maternal hormone oxytocin triggers labor [9].
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The electrical activity of neurons is a guide for the genesis of neuronal connections. Indeed,
neuronal activity exerts a key role in the development of inhibitory GABAergic synapses,
interacting closely with genetic programs. Blocking neuronal activity in developing neurons
decreases the density of inhibitory synapses, confirming an activity-dependent development
[10, 11]. The expression of GABAergic plasticity is related to modifications in the quantity of
neurotransmitter in individual vesicles. Migrating neurons express, already at an early stage, both
GABA and glutamate receptors [1], but GABA receptors are likely to be established first [12].
Interestingly, tangentially migrating interneurons express AMPA but not GABA or NMDA
receptors. Therefore, a modulation/targeting of neurons via selective activation of receptors can
be achieved [13]. This has implications for understanding and treatment of migrating disorders
affecting the nervous system.
The building of brain networks is a highly complex task which requires organized sequential
events, both spatially and from a timing standpoint. While an overdrive of GABAergic signal-
ing slows the development, the overactivity of glutamatergic signaling causes excitotoxicity
[1]. GABA receptors are the first to be active, even when synapses are still non-operant. This
creates a shunting effect preventing excitotoxicity, since the Na+ and Ca2+ spikes triggered by
GABA require only a 30–40 mV driving force. Such a shunt is part of the synergistic interac-
tions between GABA and glutamate. Thanks to these interactions, the neuronal networks in
development generate primitive patterns of discharges, observed in vivo and in cultured
networks, such as the giant depolarizing potentials (GDPs) which allow the building of func-
tional units [1]. GDPs resemble interictal-like epileptiform discharges and provide synchro-
nous Ca2+ oscillations also contributing to the development of networks. GDPs rely on the
release of GABA, glutamate, and glycine at the onset of synaptogenesis [14]. The synchronized
activity is one of the factors controlling the phenomenon of maturation [11]. Synchronization is
also achieved, thanks to gap junctions, intrinsic voltage-dependent conductance [15], and non-
vesicular paracrine release of neurotransmitters [16].
The capacity of developing nervous system to generate spontaneous activity in absence of
external stimulation is a remarkable feature that has been observed in particular in the retina,
the cerebral cortex, the hippocampus, the cerebellum, the hindbrain, and the spinal cord [14].
Recent works highlight that network bursts are driven by AMPA pathways in terms of
coordination, whereas the shaping of the dynamics of spiking activities is regulated by
NMDA- and GABA-associated currents [17].
3. Glutamate and GABA in the mature mammalian brain
3.1. Biosynthesis of glutamate and GABA: the glutamate/GABA-glutamine cycle
Glutamate and GABA do not cross the blood-brain barrier and must therefore be synthesized
within the CNS. As neurons lack the enzyme pyruvate carboxylase and therefore cannot
synthesize glutamate through the TCA cycle [18], they rely on astrocytes for the generation of
glutamate. Astrocytes generate glutamate via de novo synthesis or by “recycling” glutamine
from GABA and glutamate after reuptake. However, de novo synthesis makes up only ~15% of
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astrocytic glutamate [19]. In this reaction, pyruvate is generated from glucose during glycoly-
sis and enters the TCA after conversion to Acetyl CoA. The TCA product α-ketoglutarate can
be converted to glutamate, which is converted to glutamine by glutamine synthetase, an
enzyme that is predominately, if not exclusively, located in astrocytes [20]. Glutamine exits
astrocytes via the bidirectional N system transporters, SNAT3 and SNAT5 [21], and enter
neurons via the unidirectional system A transporters, SNAT1, SNAT2 [21], and SNAT7 [22].
There glutamine is converted back to glutamate by phosphate-activated glutaminase, an
enzyme which is expressed preferentially in neurons [23]. GABAergic neurons require an
additional step to convert glutamate to GABA through decarboxylation. After release from
the neurons, GABA and glutamate reenter the astrocytes to be “recycled” to glutamine. A small
portion of glutamate is oxidatively metabolized, thus making de novo synthesis of glutamate
necessary to maintain adequate glutamate levels [24]. The continuous recycling of glutamate,
GABA and glutamine between neurons and astrocytes is known as the glutamate/GABA-
glutamine cycle [25] (Figure 1).
3.2. Glutamatergic neurotransmission
In glutamatergic neurons, glutamate is packaged into synaptic vesicles (SVs) by vesicular
glutamate transporters (VGLUT1–3) [26]. The loaded SVs then dock near the release site,
where they are primed into a state of competence for Ca2+-triggered fusion-pore opening. Once
glutamate has been released, SVs can either fully collapse into the synaptic membrane, or close
rapidly and undock (“kiss-and-run”) [27].
Released glutamate is recognized by glutamate receptors (GluRs). Binding of glutamate
changes the receptor’s conformation and allows influx of extracellular Na+ and other cations,
and an efflux of intracellular K+ ions. GluRs fall into two major categories: ionotropic and
metabotropic [28]. Ionotropic GluRs are tetrameric ligand-gated cation channels that induce
depolarization of the postsynaptic membrane. The three types of ionotropic GluRs are named
Figure 1. Overview of the glutamate/GABA-glutamine cycle. For details see text.
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after ligands that selectively bind to one receptor only: N-methyl-D-aspartate (NMDA), alpha-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and Kainate, however all three
are bound by glutamate [28]. NMDA receptors (NMDA-Rs) activate slower than AMPA and
Kainate receptors. This delayed reaction is caused by the blockage of the cation pore of
NMDA-Rs by external Mg2+ at resting membrane potential, which is removed upon depolar-
ization of the neurons [29, 30]. Thus, non-NMDA-Rs activation is necessary to depolarize the
neurons allowing NMDA-Rs activation. NMDA-Rs also close slower than non-NMDA-Rs, and
therefore determine the duration of the synaptic current.
NMDA-Rs also allow influx of Ca2+ and have thereby a regulatory role in synaptic plasticity by
connecting synaptic activity with Ca2+-mediated biochemical signaling [31]. Depending on the
nature of the neuron’s depolarization, NMDA-Rs can both strengthen synapses, through long-
term potentiation (LTP) [32, 33], and weaken synapses, through long-term depression (LTD)
[34]. For LTP, repetitive and strong depolarization of the neurons allows significant influx of
Ca2+ into the cytoplasm and activation of protein kinases, including the calcium/calmodulin-
dependent protein kinase II (CaMKII), which (a) phosphorylate and activate AMPA-Rs and
(b) trigger the insertion of additional AMPA-Rs into the postsynaptic membrane [35]. This
increases the postsynaptic neuron’s responsiveness to glutamate leading to LTP. By strength-
ening the neighboring connections of similar activity patterns, the NMDA-R enforces the
Hebbian postulate that ‘cells that fire together, wire together’ [36]. For LTD, weak depolariza-
tion by low frequency stimulation still activates NMDA-Rs, but promotes only a modest
prolonged increase in Ca2+ levels. Protein phosphatases (protein phosphatase 1 and protein
phosphatase calcineurin) have a much higher affinity for calcium/calmodulin compared to
CaMKII and are activated at lower Ca2+ levels. Thus, under the above conditions protein
phosphatases are activated [37], dephosphorylate AMPA-Rs, and induce the removal of
AMPA-Rs from the postsynaptic membrane [38], thereby reducing the postsynaptic respon-
siveness to glutamate and leading to LTD.
Metabotropic glutamate receptors (mGluRs) [39] are overall slower acting than iGluRs. In
difference to iGluRs, mGluRs are not ion channels, but belong to a group of G-protein-coupled
receptors. The associated G-protein consists of three subunits (α, β, and γ), of which the α-
subunit is associated with GDP. Glutamate binding to the receptor induces a conformational
change that allows the replacement of GDP with GTP and consequent dissociation of the three
G-protein subunits. While the Gβ/γ-complex activates K
+ and Na+ channels, the α-subunit
interacts with different enzymes [40]. Excitatory Gα-subunits (Gαq or Gα11) bind and activate
phospholipase C-β (PLC-β), initiating a signaling cascade leading to the activation of protein
kinase C (PKC) and the release of Ca2+ from the ER. Another excitatory Gα-subunit (Gαs)
activates the membrane-associated adenylyl cyclase, which catalyzes the conversion of ATP
to cAMP, leading to activation of protein kinase A (PKA). Inhibiting Gα-subunits (Gαi or Gαo)
prevent activation of adenylyl cyclase and the activation of PKA [41]. The three mGluRs
groups (I–III) differ in their alpha subunits. Generally, Group I mGluRs carry activating Gαs
or Gα11 subunits, are localized postsynaptically, and lead to cell depolarization and increased
neuronal excitability. Groups II and III mGluRs carry inhibitory Gαi or Gαo subunits and are
often localized on presynaptic terminals or preterminal axons, where they inhibit neurotrans-
mitter release [42].
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Released glutamate must be rapidly removed to avoid continuous stimulation and exci-
totoxicity [43, 44] (see also glutamate-induced excitotoxicity). Glutamate uptake is mediated
via brain excitatory amino acid transporters (EAATs) on both pre- and postsynaptic neurons
and on surrounding astrocytes [45]. Five subtypes of EAATs (EAAT1–5) have been cloned so
far. A smaller portion of extracellular glutamate is reabsorbed by presynaptic or postsynaptic
neurons.
Another mechanism involved in the extracellular glutamate regulation is the cystine/gluta-
mate exchange transporter xc(). In contrast to the EAATs, xc() is involved in elevating
extracellular glutamate concentrations. Here intracellular glutamate is exchanged for extracel-
lular cystine. The stimulation of xc() modulates glutamate release from the presynaptic
neurons [46]. xc() regulates glutamate homeostasis through the involvement of the presyn-
aptic mGluR2/3. Moreover, a decrease of xc() expression can lead to a reduction in
extrasynaptic glutamate level. This effect may cause a loss of glutamatergic tone on presynap-
tic mGluR2/3, which can lead to a marked increase in glutamate release from presynaptic
glutamatergic neurons [47].
3.3. GABAergic neurotransmission
For the synthesis of GABA, glutamate is decarboxylated to GABA by glutamate decarboxylase
(GAD). GAD is expressed as two isoforms (GAD67 and GAD65) and can be found only in
GABAergic neurons and in certain peripheral tissues, most prominently in the pancreatic islets
[48]. GABA can also be taken up by presynaptic neurons after its release into the synapsis.
However, this recycled GABA is mainly metabolized to generate ATP through the GABA
shunt pathway [49], while newly synthesized GABA is preferentially taken up into SVs [49].
Transport of newly synthesized GABA into SVs is tightly linked to its synthesis, as GAD65 and
the GABA transporter VGAT form a protein complex with chaperone protein HSC70, the
vesicular cysteine string protein (CSP), and CaMKII [49]. In the absence of GAD65 from this
complex, the active site of VGAT may be available to cytosolic GABA, and vesicular transport
of GABA can be restored to a certain extent [49]. GAD65 has also a crucial role in the
trafficking of GABAergic vesicles to presynaptic clusters [50]. Palmitoylation of cysteine resi-
dues located at the N-terminus of GAD65 is required for the transport of GAD65 to synaptic
terminals [51], and decreased palmitoylation impairs GABAergic neurotransmission, as
observed in Huntington’s disease [52]. Similar to glutamate, GABA is released in a Ca2+-
dependent manner upon depolarization of the presynaptic membrane.
GABA receptors present as ionotropic GABAA receptors that cause rapid inhibitory postsyn-
aptic potentials, and metabotropic GABAB receptors that cause slow inhibitory postsynaptic
potentials [53]. GABAA receptors are multi-subunit proteins [54] and consist of three major
subunits (α, β, and γ). A total of five subunits are arranged around the central ion pore. The
major receptor isoform consists of two α1, two β2, and one γ2 subunits. GABA binding to
GABAA receptors on the postsynaptic neuron induces rapid and transient opening of GABAA
receptor Cl channels [55]. The subsequent influx of anions hyperpolarizes the membrane
(phasic inhibition). GABA overspill can activate extrasynaptical GABAA receptors, inducing a
more prolonged opening of the ion channel (tonic inhibition) [56].
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Metabotropic G-protein coupled GABAB receptors are mostly located extrasynaptically and
can be found both pre- and the postsynaptical. These heterodimers consist of GABAB1 and
GABAB2 subunits. The GABAB1 subunit can be bound by GABA, while GABAB2 is coupled to
the G-protein. Activation of GABAB receptors induces the dissociation of the subunits of the
coupled G-protein. The Gβ/γ-subunit complex activates inwardly rectifying K
+ channels [57]
and inhibits voltage-activated Ca2+ channels [58], resulting in hyperpolarization of the neuron
and inhibition of neurotransmission [59]. The Gαi-subunit inhibits activation of adenylyl
cyclase as described above for mGluR. Activation of presynaptical GABAB receptors impedes
opening of voltage-activated Ca2+ channels and thereby reduces neurotransmitter release.
Thus GABA can inhibit its own release through a negative feedback loop via GABAB receptors
present on GABAergic axons [60]. Activation of postsynaptical GABAB receptors reduces
depolarization of the plasma membrane and thereby modulates excitatory signals.
The reuptake of GABA is mediated by GABA transporter protein present in presynaptic nerve
terminals (GAT-1) and surrounding glial cells (GAT-3) [61].
3.4. Neurological diseases associated with glutamate and GABA receptors and GABA
release mechanisms
3.4.1. Limbic encephalitis
The relation between anti-GluR antibodies (Abs) with limbic encephalitis has been investi-
gated during the last two decades [62, 63]. Several autoantibodies against extracellular epi-
topes of GluR involved in synaptic transmission and plasticity, such as AMPA-Rs [64] and
NMDA-Rs [65] are described. The affected patients develop complex neuropsychiatric symp-
toms, such as memory deficits, cognition impairment, psychosis, seizures, abnormal move-
ments, or coma. These disorders affect mainly young women, though cases of men and
children have been reported [62]. Some of these patients present with malignant tumors and
the syndrome can be qualified as paraneoplastic [62], characterized by association of anti-
NMDA-RAb in ovarian teratoma and anti-AMPA-RAb in lung small cell carcinoma.
Paraneoplastic limbic encephalitis can be fatal, but is curable if treated at an early stage by
surgical removal of the tumor and a combination of immunotherapeutic agents [62]. Mecha-
nistically, autoantibodies directed against AMPA-Rs and NMDA-Rs decrease the numbers of
the cell-surface receptors [63] and anti-AMPA-RAb may act as agonists and increase cell
excitability [66].
3.4.2. Immune-mediated cerebellar ataxias
Compared with autoimmune encephalitis affecting the limbic system, autoantibodies to
GluRs, such as anti-mGluR1 Ab and anti-glutamate receptor delta2 (GluRδ2) Ab, are less
frequently associated with immune-mediated cerebellar ataxias (IMCAs). Anti-mGluR1Ab
was reported in two patients with malignant lymphoma and one patient with prostate adeno-
carcinoma [67, 68]. Anti-mGluR1Ab impairs the induction of LTD, which causes ataxia in mice
[67]. Interestingly, IMCAs associated with anti-GluRδ2Ab are always preceded or accompa-
nied by either infection or vaccination [58]. Polyclonal Abs toward the putative ligand-binding
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site of GluRδ2 are known to cause AMPA-R endocytosis and attenuate their synaptic trans-
mission, resulting in the development of ataxia in mice [69].
3.4.3. Autosomal recessive cerebellar degeneration
Autosomal recessive CAs (ARCAs) are affected by several gene mutations. One of these
involves mutations in the GRM1 gene, which encodes mGluR1, known to play an important
role in cerebellar differentiation [70]. Accordingly, the clinical features of this familial form of
CAs appear already during childhood. The child shows global developmental delay, intellec-
tual defects, severe CAs, and pyramidal signs. Brain imaging often shows progressive gener-
alized cerebellar atrophy. Mutations affect a gene region critical for alternative splicing and the
formation of the receptor structure.
3.4.4. Glutamate-induced excitotoxicity
Deficits and mutations in GluR can also affect the level of extracellular glutamate with detri-
mental outcomes for neurotransmission and neuronal health. The level of extracellular gluta-
mate is determined by three factors: (1) vesicular-released glutamate at the synapses, (2) non-
vesicular-released glutamate from the system xc() (see above) [71], and (3) glutamate uptake
by EAATs on astrocytes [72]. When glutamate release exceeds glutamate uptake, the excess
glutamate activates a large number of postsynaptic NMDA-Rs, resulting in the induction of
excitotoxic neuronal death by allowing excessive Ca2+ influx through the receptor-operated
cation channels [73]. Excessive activation of NMDA-Rs and the associated Ca2+ influx result in
stimulation of calpain I and nNOS [73]. This causes DNA damage and formation of ONOOd
due to excess NO (nitrosative stress) and other free radicals. The combination of these two
changes ultimately leads to mitochondrial dysfunction and cell death [73]. Recent studies
reported the presence of high glutamate levels in the extracellular space in chronic degenera-
tive diseases, such as amyotrophic lateral sclerosis, Alzheimer’s disease, and Huntington’s
disease [74]. Taken together, glutamate-induced excitotoxicity may be a common process for
neuronal death throughout the CNS and accelerates the original pathological changes.
3.4.5. Neurological diseases associated with deficits in GABA receptors
Anti-GABAB receptor Ab is associated with limbic encephalitis [75], which manifests clinically
similar to anti-GluRAb-mediated limbic encephalitis. Some patients also develop CAs. About
50% of the patients have neoplastic diseases, especially small cell lung carcinoma [75]. Clinical
studies indicate that surgical removal of the lung tumor and subsequent immunotherapy can
be effective in the relief of the above neurological disorders, especially in the early stages of
disease.
3.4.6. Association of GAD65 dysfunction with neurological disorders
Anti-GAD65Abs are associated with stiff-person syndrome (SPS) and CAs [76]. Titers of anti-
GAD65Ab are high (>1000 U/ml) in both conditions. SPS is characterized clinically by progressive
rigidity and painful-muscle spasms in the axial and limb muscles. Electromyography (EMG)
shows simultaneous activities of the agonist and antagonistic muscles. Anti-GAD65Ab-associated
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CAs affect mostly women in their 50–60s and exhibit subacute or chronic CAs, which are
sometimes associated with SPS or epilepsy [76]. Furthermore, the majority of patients also suffer
from type 1 diabetes mellitus (T1D) [76].
Based on the intracellular location of GAD65 (on the cytoplasmic side of SVs), the pathogenic
role of anti-GAD65Ab in CA and SPS has been questioned. However, recent studies have shed
new light on this issue. First, the pathogenic actions of anti-GAD65Ab have been clarified both
in in vitro and in vivo preparations [77–82], for example, the Cerebrospinal fluid (CSF) of
patients with SPS inhibited GABA synthesis [83]. Furthermore, SPS-like symptoms were
reproduced in experimental rats and mice injected intrathecally or intraventricularly [84] or
intracerebellarly [80] with IgGs obtained from the CSF of CA and SPS patients. Specifically,
IgGs obtained from the CSF of patients with anti-GAD65Ab-associated CA depressed GABA
release in cerebellar brain slices [77, 78, 82, 85], and their intracerebellar injection interfered
with cerebellar control of the motor cortex and resulted in ataxic gait in rats [79]. These actions
were reproduced by human anti-GAD65 monoclonal Ab b78, which binds to an epitope
similar to that recognized in SPS patients positive for anti-GAD65Ab [80–82].
Second, studies in animals have shown internalization of antibodies by cerebellar neurons [81,
86], demonstrating that anti-GAD65Ab can access their intracellular target. Together, these
results indicate the possibility that anti-GAD65Ab may damage sufficient numbers of
GABAergic neurons to result in the appearance of frank neurological symptoms [87].
The pathological effects of anti-GAD65Ab depend on epitope specificity. Specifically, the
pathologic effects of anti-GAD65Abs on GABA synthesis and release were specific to anti-
GAD65Ab b78—representing SPS- and CA-associated anti-GAD65Ab—and could not be
reproduced by monoclonal anti-GAD65Ab b96.11, representing an epitope specificity associ-
ated with type 1 diabetes mellitus [80–82]. This epitope dependence might explain the differ-
ences in neurological phenotypes. Administration of CSF obtained from patients with SPS or
CAs reproduced the clinical features of the corresponding disease in mice [80]. Thus anti-
GAD65Ab in SPS that inhibit GABA synthesis, would attenuate inhibitory Purkinje cell-
mediated depression of the spino-cerebellar loop, resulting in increased muscle tone, whereas
anti-GAD65Ab in CAs depress GABA release, resulting in disruption of Purkinje cell-mediated
modulation of the cerebro-cerebellar loop to elicit disorganized movements [87]. An alterna-
tive explanation of the phenotypic differences is the involvement of other autoimmune-
mediated mechanisms.
In anti-GAD65Ab-associated CAs, anti-GAD65Ab impairs the association of GAD65 with the
cytosolic side of SVs resulting in a decrease in vesicular GABA contents with low release
probability [82]. Under normal conditions, the released GABA spills over to the neighboring
excitatory synaptic terminals and inhibits presynaptic glutamate release through GABA recep-
tors. However, this GABA-induced inhibition of glutamate release is disturbed in patients with
CAs [77]. Taken together, anti-GAD65Ab elicit marked imbalance in neurotransmitters; includ-
ing a decrease in GABA and an increase in glutamate. The imbalance between GABA and
glutamate is accelerated following the involvement of microglia and astrocytes [87]. Microglia
activated by excessive glutamate levels can secrete various cytokines, which facilitate gluta-
mate release presumably through xc() on microglia, and suppress the uptake of glutamate
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through EAATs on astrocytes [71, 88, 89]. Thus, the neuroinflammation-induced chain reac-
tions accelerate the imbalance, leading to profound excitotoxicity. In agreement with this
notion, the cerebellar neurons are completely lost in patients with advanced stage CAs [90].
In conclusion, deficits in glutamate- and GABA-mediated synaptic mechanisms, upset the
glutamate/GABA ratio. Notably, the level of glutamate is relatively high compared with that
of GABA, caused by various etiologies, including glutamate release by damage-induced depo-
larization, exaggerated glutamate release through xc(), and attenuated uptake of glutamate
through EAATs, or a decrease in GABA release with subsequent increase in glutamate release.
The imbalance between glutamate and GABA can trigger excitotoxicity, one of several neuron
death mechanisms.
4. GABA/glutamate signaling pathways in pancreatic islets and
implications in type 1 diabetes mellitus
While GABA and glutamate are best characterized for their role as neurotransmitter, they are
also involved in extra-neuronal signaling. As a major building block in proteins synthesis,
intracellular glutamate is abundantly present in the body. In contrast, GABA is present only in
restricted non-neuronal tissues, including the pancreas [91]. Pancreatic islets are clusters of
endocrine cells located in the exocrine pancreas and regulate blood glucose homeostasis. An
islet typically contains insulin-releasing beta cells, glucagon-secreting alpha cells, somatostatin-
containing delta cells, and pancreatic polypeptide-producing (PP) cells. The metabolic actions
of insulin and glucagon are reviewed in great detail elsewhere [92]. Briefly, insulin is released at
elevated blood glucose levels and acts as an anabolic hormone, causing cellular glucose uptake
primarily in skeletal muscles, the liver, and fat tissue. Here glucose is converted to storable
energy substrates including glycogen and triglycerides, respectively. At low blood glucose
levels, glucagon is secreted from pancreatic alpha cells. Glucagon causes the liver to convert
stored glycogen to glucose and induces lipolysis in fat tissue. Many regulatory mechanisms
are in place to control the secretion of insulin and glucagon to maintain stable blood glucose
levels. Within the islet, extracellular insulin inhibits glucagon secretion from alpha cells, while
glucagon enhances both insulin and somatostatin secretion [93]. In recent years, GABA and
glutamate have gained interest for their respective roles in the regulation of secretion of insulin
and glucagon.
In the following sections, we will review GABAergic and glutamatergic signaling in the islets
of Langerhans and possible implications for type 1 diabetes mellitus.
4.1. Glutamate and GABA in pancreatic islets
Both glutamate and GABA are synthesized from glucose taken up by beta cells. The majority
of glucose is metabolized to produce energy, however a portion is converted to glutamate. The
initial step is catalyzed by pyruvate carboxylase present in the beta cells [94]. Thus, in contrast
to GABAergic neurons, beta cells can synthesize glutamate on their own. In the alpha cells,
glutamate is loaded into glucagon-containing secretory granules via VGLUT1 and VGLUT2
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[95]. Within the beta cells, glutamate is decarboxylated by GAD to yield GABA. GABA is
packaged by the GABA transporter VGAT into small synaptic-like microvesicles (SLMVs)
[96]. A smaller fraction of GABA is present in insulin-containing large dense core vesicles
(LDCVs) [97, 98]. These vesicles also express VGAT, suggesting similar packaging mechanisms
as for SLMVs [98]. GABA is present predominantly, if not exclusively, in the beta cells [96, 99,
100], and GABA and GAD expression levels in beta cells are similar to those in GABAergic
neurons [97].
Both isoforms of GAD have been identified in pancreatic beta cells, GAD65 being the predom-
inant isoform in rat and human beta cells, while mice beta cells only express GAD67 [48]. In
human and rat beta cells GAD65 co-localizes with GABA at the SLMVs [101], while in murine
pancreatic islets, GAD67 is firmly membrane anchored and efficiently transits to presynaptic
clusters [102]. It remains unclear whether GAD is involved in SLMVs transport to the plasma
membrane, in analogy to GABAergic neurons (see also Section 3.3).
As outlined above, GABA is present in both SLMVs and insulin-containing LDCVs. The basal
release of GABA from beta cells is relatively constant [101, 103], but can be modulated
depending on the metabolic state of the cell [104]. The mechanisms involved in GABA release
were first investigated in beta cell lines, where GABA secretion was shown to be dependent on
the presence of extracellular Ca2+ [105], suggesting that GABA is released in response to an
increase in cytosolic Ca2+ levels. A detection system for GABA release involving overexpressed
GABAA receptors in dispersed rat islets allowed the sensitive detection of GABA release as
fluctuations in current in whole-cell patch-clamped beta cells [106]. These studies confirmed
that GABA release is dependent on the entry of extracellular Ca2+ through voltage-gated
channels and not by membrane depolarization itself. The study further indicated that the
observed GABA release originated predominantly from SLMVs rather than LDCVs.
Both beta and alpha cells express GABAA and GABAB receptors [103]. Through the expression
of GABA receptors on beta cells, GABA regulates its own secretion (autocrine regulation).
GABAA receptor activation induces further GABA release (autocrine positive feedback loop)
[97, 107]. However, GABA-mediated regulation of GABA release depends on the extracellular
glucose concentration. At high glucose concentrations, GABA hyperpolarizes the membrane of
isolated beta cells and beta cell lines [108]. This inhibitory effects appears be mediated via
GABAB receptors [106, 109].
Presence of GABA receptors on adjacent alpha cells enables a paracrine regulation of these
cells [110]. Activation of GABAA receptors on alpha cells leads to hyperpolarization and
suppression of glucagon and glutamate secretion [103, 111]. As glucagon and glutamate
trigger insulin release from beta cells, GABAergic inhibition of glucagon and glutamate secre-
tion indirectly downregulates insulin release from beta cells as a negative feedback regulation
(Figure 2). Extracellular GABA is taken up by the plasma membrane GABA transporter GAT3
expressed on both alpha and beta cells [98].
At low concentrations of glucose, alpha cells show high action potentials [103, 112], mediated
by voltage-gated Na+ and Ca2+ channels [113]. This triggers the release of glucagon and
glutamate. At high glucose concentrations, release of glucagon and glutamate is inhibited,
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although the mechanistic details of this regulation remain unclear. Paracrine GABA-mediated
regulation (as described above) is suggested by the finding that isolated rat alpha cells no
longer show reduced glucagon/glutamate release at elevated glucose concentrations [112], and
the observation that in rat islets and purified alpha cells, GABA antagonists suppress glucagon
secretion [114]. Insulin and GABA are suggested to serve as paracrine inhibitors of glutamate
and glucagon release [101, 103, 115].
Once released, glutamate activates GluRs expressed on both alpha and beta cells. The cell-
specific distribution of AMPA-R/Kainate receptors and NMDA-Rs remains debated, and earlier
reports suggested that AMPA-Rs are expressed exclusively on alpha cells, while NMDA-Rs were
reported to be specifically expressed on beta cells [116]. However, later reports suggest that
AMPA-Rs are also expressed on mouse beta cells, and other studies suggest iGluRs expression
only on alpha and not on beta cells [117]. mGluRs mGluR8, mGluR5 and mGluR2/3 are
expressed by beta cells [109, 118], while mGluR4 protein is expressed on alpha cells [119].
Extracellular glutamate activates AMPA/kainate Rs present on alpha cells and triggers the co-
release of glutamate and glucagon (positive feedback regulation) [117, 120, 121]. On the other
hand, activation of mGluR inhibits glucagon/glutamate secretion from alpha cells [119] (nega-
tive feedback regulation). Few studies reported that activation of AMPA/Kainate-R and/or
mGluR on beta cells triggers insulin secretion [118, 120], however subsequent studies could
not confirm these results [117]. Still, through glucagon-mediated insulin release from beta cells,
co-secreted glutamate indirectly stimulates insulin secretion from beta cells [121]. In addition,
glutamate stimulates GABA release from SLMVs in beta cells independently of insulin release,
Figure 2. Schematic outline of presumed GABAergic and glutamatergic signaling in pancreatic islets. At low glucose
concentrations, beta cells release GABA in a glucose-independent manner [97, 108]. This tonic GABA release continuously
activates GABAA receptors on beta cells and alpha cells. GABAA receptor activation leads to further GABA release from
beta cells and suppresses release of glucagon and glutamate from alpha cells, thereby preventing insulin secretion. As
extracellular glucose levels rise, the level of intracellular Ca2+ increases in beta cells, allowing release of insulin. Secreted
insulin inhibits GABAA receptors on the beta cells, thereby decreasing the autocrine positive feedback release of GABA
from beta cells and reducing GABA-mediated inhibition of alpha cells [140]. Moreover, under high glucose concentrations
GABA inhibits its own release from beta cells (via GABAB receptor activation). Reduced extracellular GABA concentra-
tions allow glucagon and glutamate secretion from alpha cells. Glutamate triggers glutamate and glucagon release via
activation of AMPA-Rs and glucagon stimulates further insulin release from beta cells. Counter-regulation: eventually, the
depolarization of beta cells activates NMDA-Rs present on beta cells, initiating the repolarization of beta cells and limiting
insulin release. Reduced insulin levels lift the inhibition of GABAA receptors on beta cells and allow positive feedback
regulation of GABA release. Elevated extracellular GABA levels can now activate GABAA receptors on alpha cells and
inhibit glutamate and glucagon release. Of note, insulin secretion induces GABAA receptors phosphorylation and trans-
location to alpha cell plasma membrane [111]. This renders alpha cells more susceptible to GABA-mediated suppression
of glucagon secretion, and ultimately limits insulin secretion from beta cells [111, 141].
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thus serving as a regulatory factor to limit glucagon/glutamate release [106]. As in the
GABAergic system, glutamate-mediated regulation of beta cells depends on the extracellular
glucose concentration. The high-affinity NMDA-Rs on the beta cell are already saturated at
physiological glutamate concentrations in the islet, and are mainly activated through depolar-
ization of beta cells [121]. As islets are depolarized by external glucose, the NMDA-R-mediated
repolarization of the beta cells is a negative feedback regulation of glucose-stimulated insulin
secretion. Extracellular glutamate is taken up by EAAT1 and 2 expressed on alpha cells [122].
4.2. Proposed GABAergic and glutamatergic signaling in type 1 diabetes mellitus
Type 1 diabetes mellitus (T1D) is an autoimmune disease, characterized by the specific
destruction of pancreatic beta cells. Exogenous administration of insulin is necessary to avoid
hyperglycemia. Additionally, within 5 years of disease diagnosis, almost all patients with T1D
lose their ability to generate an adequate glucagon response to hypoglycemia [123]. This loss
has been attributed to the lack of intracellular regulation of beta- to alpha-cell signaling during
hypoglycemia [124] and may account for the elevated plasma glucagon levels in diabetes
patients, indicating alpha-cell hypersecretion [125, 126]. As observed for neurons, beta cells
are sensitive to elevated extracellular glutamate levels and show signs of secretory defects and
apoptosis at high glutamate levels [122]. This effect was not prevented by AMPA-R and
Kainate-R antagonists and therefore unlikely caused by excitotoxicity. Instead, oxidative stress
appears to be the underlying mechanism of glutamate-induced beta-cell death. As outlined in
detail in the CNS portion of this chapter, the glutamate/cystine antiporter system xc()
exchanges intracellular glutamate for extracellular cystine. Excess extracellular glutamate
inhibits and/or reverts the activity of the antiporter, thus depleting the cells of cysteine, a
building block of the antioxidant glutathione, possibly increasing the cells’ vulnerability to
oxidative stress [122]. Upregulation of EAAT1 expression on beta cells protects beta cells from
glutamate-induced toxicity [122], indicating glutamate signaling as a potential therapeutic
target. Notably, many effective antidiabetic drugs such as GLP-1, exenatide, and glitazones
also show significant neuroprotective activity against glutamate-induced cytotoxicity in the
brain [127, 128]. Moreover, topiramate, an anti-epileptic drug that provides neuroprotection by
preventing glutamate toxicity, has antidiabetic and beta-cell cytoprotective effects [129] and
long-lasting remission was observed in a T1D patient after treatment with topiramate for
generalized seizures [130].
GABA has an overall anti-inflammatory effect on the immune system [131]. GABAA receptors
are expressed by T cells, B cells, and other mononuclear cells, and their activation suppresses
lymphocyte proliferation [132, 133]. This GABA-mediated inhibition of T cell responses may
provide the mechanism of GABA-associated protection of animal models for development of
T1D [134]. GABA also promotes a shift from an inflammatory to an anti-inflammatory cyto-
kine profile in vivo and in vitro [107]. Another aspect of GABA activity in regard to pancreatic
beta cells has been only recently reported. Through activation of GABAB receptors, GABA
significantly increases beta-cell viability [135] and replication [136]. In mouse models, GABA
administration prevented and even reversed T1D [107]. One of the involved mechanisms may
be GABA-mediated conversion of alpha cells to beta cells [137, 138]. While the details of the
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mechanisms involved need to be further investigated, these studies open the intriguing poten-
tial to use GABA treatment to re-generate beta cells in T1D [139].
It remains unclear what may cause impaired GABAergic and glutamatergic signaling in the
pancreatic islets. No mutations of receptors or other elements of the signaling mechanisms
have been identified in T1D so far. GAD65Ab are present in the majority of patients with T1D
and are regarded as a byproduct of the immune response without significant relevance for the
disease progression. However, it is possible that in analogy to their role in neurological
disorders, GAD65Ab are taken up by pancreatic beta cells and (a) uncouple the balanced
regulation of insulin and glucagon secretion and (b) induce beta cell apoptosis through
prolonged exposure to elevated extracellular glutamate levels. Further research is needed to
determine whether GAD65Ab have a pathologic role in the development of T1D.
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